药康生物
(688046)
| 流通市值：49.65亿 | | | 总市值：49.65亿 |
| 流通股本：4.10亿 | | | 总股本：4.10亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 170,855,596.98 | 686,837,009.6 | 509,718,216.98 | 340,382,982.48 |
| 营业收入 | 170,855,596.98 | 686,837,009.6 | 509,718,216.98 | 340,382,982.48 |
| 二、营业总成本 | 135,710,404.13 | 580,186,527.9 | 414,793,749.59 | 267,437,468.2 |
| 营业成本 | 63,123,361.52 | 261,052,207.72 | 185,294,724.73 | 120,753,421.84 |
| 税金及附加 | 965,377.16 | 3,899,209.64 | 2,341,091.34 | 1,293,775.52 |
| 销售费用 | 24,733,025.19 | 107,148,190.94 | 72,776,952.72 | 44,912,025.63 |
| 管理费用 | 30,914,953.95 | 132,536,070.83 | 97,657,073.04 | 64,720,177.87 |
| 研发费用 | 18,257,390.7 | 87,133,668.26 | 62,993,920.42 | 40,983,726.12 |
| 财务费用 | -2,283,704.39 | -11,582,819.49 | -6,270,012.67 | -5,225,658.78 |
| 其中:利息费用 | 1,077,444.95 | 4,300,850.78 | 3,348,055.67 | 2,158,247.48 |
| 其中:利息收入 | 2,229,092.48 | 14,388,671.43 | 10,897,843.98 | 7,052,840.52 |
| 加:公允价值变动收益 | 1,156,726.13 | 2,341,561.65 | 2,296,950.81 | 2,374,465.87 |
| 加:投资收益 | 289,597.86 | 8,003,815.54 | 7,638,844.93 | 6,723,297.37 |
| 资产处置收益 | -56,116.99 | 12,516.02 | -4,740.32 | - |
| 资产减值损失(新) | -5,887,176.39 | -21,644,970.29 | -16,682,081.69 | -12,775,185.21 |
| 信用减值损失(新) | -3,174,098.09 | -3,276,607.77 | -9,507,795.12 | -8,108,398.41 |
| 其他收益 | 3,199,528.58 | 27,281,008.72 | 20,545,093.46 | 16,258,223.53 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0.01 |
| 四、营业利润 | 30,673,653.95 | 119,367,805.57 | 99,210,739.46 | 77,417,917.44 |
| 加:营业外收入 | 0.01 | 14,012.15 | 4.28 | 1.48 |
| 减:营业外支出 | - | 166,819.78 | 11,824.73 | 7,533.49 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 30,673,653.96 | 119,214,997.94 | 99,198,919.01 | 77,410,385.43 |
| 减:所得税费用 | 693,393.56 | 9,395,178.64 | 984,540.41 | 1,072,667.78 |
| 六、净利润 | 29,980,260.4 | 109,819,819.3 | 98,214,378.6 | 76,337,717.64 |
| 持续经营净利润 | 29,980,260.4 | 109,819,819.3 | 98,214,378.6 | 76,337,717.64 |
| 归属于母公司股东的净利润 | 29,980,260.4 | 109,819,819.3 | 98,214,378.6 | 76,337,717.64 |
| (一)基本每股收益 | 0.07 | 0.27 | 0.24 | 0.19 |
| (二)稀释每股收益 | 0.07 | 0.27 | 0.24 | 0.19 |
| 八、其他综合收益 | -98,315.24 | 7,553,752.88 | -198,986.15 | 138,212.38 |
| 归属于母公司股东的其他综合收益 | -98,315.24 | 7,553,752.88 | -198,986.15 | 138,212.38 |
| 九、综合收益总额 | 29,881,945.16 | 117,373,572.18 | 98,015,392.45 | 76,475,930.02 |
| 归属于母公司股东的综合收益总额 | 29,881,945.16 | 117,373,572.18 | 98,015,392.45 | 76,475,930.02 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-31 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |